Key result
ANP augments beta-adrenergic cardiomyocyte contractility in early cardiac hypertrophy via phosphodiesterase redistribution.
Why the study?
The role of different cAMP and cGMP microdomains and their changes in early cardiac disease are not well understood.
Redistribution of cGMP-regulated phosphodiesterases in early cardiac hypertrophy augments cGMP-mediated contractility, representing a potential compensatory mechanism to sustain heart function.
Answers are grounded in this paper and cite their sources.
Potential compensatory mechanism in early hypertrophy; hypothesis-generating for PDE-targeted cGMP modulation in human HF.
Rationale : Cyclic nucleotides are second messengers that regulate cardiomyocyte function through compartmentalized signaling in discrete subcellular microdomains. However, the role of different microdomains and their changes in cardiac disease are not well understood. Objective : To directly visualize alterations in β-adrenergic receptor–associated cAMP and cGMP microdomain signaling in early cardiac disease. Methods and Results : Unexpectedly, measurements of cell shortening revealed augmented β-adrenergic receptor–stimulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardiac hypertrophy after transverse aortic constriction, which was in sharp contrast to well-documented β-adrenergic and natriuretic peptide signaling desensitization during chronic disease. Real-time cAMP analysis in β 1 - and β 2 -adrenergic receptor–associated membrane microdomains using a novel membrane-targeted Förster resonance energy transfer–based biosensor transgenically expressed in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by spatial redistribution of cGMP-sensitive phosphodiesterases 2 and 3 between both receptor compartments. Functionally, this led to a significant shift in cGMP/cAMP cross-talk and, in particular, to cGMP-driven augmentation of contractility in vitro and in vivo. Conclusions : Redistribution of cGMP-regulated phosphodiesterases and functional reorganization of receptor-associated microdomains occurs in early cardiac hypertrophy, affects cGMP-mediated contractility, and might represent a previously not recognized therapeutically relevant compensatory mechanism to sustain normal heart function.
No takes yet. Share an insight, caveat, or question.
Perera et al. (2015) studied Early cardiac hypertrophy. Transverse aortic constriction (TAC) and Atrial natriuretic peptide (ANP) was evaluated on Cardiomyocyte contractility / cell shortening. Atrial natriuretic peptide signaling augmented beta-adrenergic receptor-stimulated cardiomyocyte contractility in early cardiac hypertrophy via spatial redistribution of phosphodiesterases.
Synapse has enriched 10 related papers. Consider them for comparative context: